This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Parker, B. Articles by Bruce, I. Search for Related Content PubMed PubMed Citation Articles by Parker, B. Articles by Bruce, I. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Lupus Steroids Hazardous Substances DB METHYLPREDNISOLONE Social Bookmarking                   What's this?

High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus

The Kellgren Centre for Rheumatology, Central Manchester and Manchester Children's NHS Trust, Manchester Royal Infirmary

IN Bruce

The Kellgren Centre for Rheumatology, Central Manchester and Manchester Children's NHS Trust, Manchester Royal Infirmary, ARC Epidemiology Unit, The University of Manchester, Manchester, UK, ian.bruce{at}manchester.ac.uk

The pharmacological armamentarium for the treatment of SLE is expanding and a number of novel therapies are currently under investigation. In spite of this, steroid therapy remains the cornerstone of treatment and intravenous methylprednisolone (IVMP) is still widely used in clinical practice. There is however surprisingly little evidence on which to define its precise role. The objective of this review was to consider the published evidence relating to the use of IVMP in SLE patients and also to identify open questions that still need to be answered with regard to its use.

In acute flares, IVMP induces rapid suppression of acute inflammation. There is not however a strong evidence base to support the use of high doses compared to low IVMP doses or oral prednisolone. In maintenance regimes, secondary analyses suggest that IVMP may confer additional long-term renal survival over oral steroids as part of a cyclophosphamide regime. Therefore, in addition to the evaluation of novel therapies for SLE, better evidence to define the precise role of IVMP in SLE is still required. (Lupus (2007) 16, 387—393)

Key Words: corticosteroids • methylprednisolone • systemic lupus erythematosus.

Lupus, Vol. 16, No. 6, 387-393 (2007)
DOI: 10.1177/0961203307079502


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				I. Tatsuno, T. Sugiyama, S. Suzuki, T. Yoshida, T. Tanaka, M. Sueishi, and Y. Saito Age Dependence of Early Symptomatic Vertebral Fracture with High-Dose Glucocorticoid Treatment for Collagen Vascular Diseases J. Clin. Endocrinol. Metab., May 1, 2009; 94(5): 1671 - 1677. [Abstract] [Full Text] [PDF]

				C. A. Heyneman Systemic Lupus Erythematosus: A Therapeutic Update Journal of Pharmacy Practice, February 1, 2009; 22(1): 29 - 52. [Abstract] [PDF]